Cancer Research Prevention Award  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 8307, September 1, 2007. doi: 10.1158/0008-5472.CAN-07-1687
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mawji, I. A.
Right arrow Articles by Schimmer, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mawji, I. A.
Right arrow Articles by Schimmer, A. D.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

A Chemical Screen Identifies Anisomycin as an Anoikis Sensitizer That Functions by Decreasing FLIP Protein Synthesis

Imtiaz A. Mawji1, Craig D. Simpson1, Marcela Gronda1, Moyo A. Williams1, Rose Hurren1, Clare J. Henderson1, Alessandro Datti2, Jeffrey L. Wrana2 and Aaron D. Schimmer1

1 Ontario Cancer Institute, Princess Margaret Hospital and 2 Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada

Requests for reprints: Aaron D. Schimmer, Ontario Cancer Institute, Princess Margaret Hospital, 610 University Avenue Toronto, ON, Canada M5G 2M9. Phone: 416-946-2838; E-mail: aaron.schimmer{at}utoronto.ca.

Malignant epithelial cells with metastatic potential resist apoptosis that normally occurs upon loss of anchorage from the extracellular matrix, a process termed "anoikis." Resistance to anoikis enables malignant cells to survive in an anchorage-independent manner, which leads to the formation of distant metastases. To understand the regulation of anoikis, we designed, automated, and conducted a high-throughput chemical screen for anoikis sensitizers. PPC-1 anoikis–resistant prostate cancer cells were seeded in hydrogel-coated ultralow binding plates for suspension conditions and standard tissue culture plates to promote adhesion. After seeding, cells were treated with aliquots from a library of previously characterized small molecules, and viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, assay. From this chemical screen, we identified anisomycin that induced apoptosis in suspension conditions, but was not toxic to these cells grown under adherent conditions. Anisomycin sensitized cells to anoikis by decreasing levels of the caspase-8 inhibitor FLIP and subsequently activating the death receptor pathway of caspase activation. Although anisomycin activated c-Jun-NH2-kinase and p38, these kinases were not functionally important for the effect of anisomycin on anoikis and FLIP. Rather, anisomycin decreased FLIP and sensitized cells to anoikis by inhibiting its protein synthesis. Finally, we showed that anisomycin decreased distal tumor formation in a mouse model of prostate cancer metastases. Thus, a novel chemical screen identified anisomycin as an anoikis sensitizer that acts by decreasing FLIP protein synthesis. Our results suggest that FLIP is a suppressor of anoikis and inhibiting FLIP protein synthesis may be a useful antimetastatic strategy. [Cancer Res 2007;67(17):8307–15]




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. D. Simpson, I. A. Mawji, K. Anyiwe, M. A. Williams, X. Wang, A. L. Venugopal, M. Gronda, R. Hurren, S. Cheng, S. Serra, et al.
Inhibition of the Sodium Potassium Adenosine Triphosphatase Pump Sensitizes Cancer Cells to Anoikis and Prevents Distant Tumor Formation
Cancer Res., April 1, 2009; 69(7): 2739 - 2747.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Parsons, P. Patel, D. J. Brat, L. Colbert, and P. M. Vertino
Silencing of TMS1/ASC Promotes Resistance to Anoikis in Breast Epithelial Cells
Cancer Res., March 1, 2009; 69(5): 1706 - 1711.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. B. Zavareh, K. S. Lau, R. Hurren, A. Datti, D. J. Ashline, M. Gronda, P. Cheung, C. D. Simpson, W. Liu, A. R. Wasylishen, et al.
Inhibition of the Sodium/Potassium ATPase Impairs N-Glycan Expression and Function
Cancer Res., August 15, 2008; 68(16): 6688 - 6697.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Travert, P. Ame-Thomas, C. Pangault, A. Morizot, O. Micheau, G. Semana, T. Lamy, T. Fest, K. Tarte, and T. Guillaudeux
CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-{kappa}B Activation and Up-Regulation of c-FLIP and Bcl-xL
J. Immunol., July 15, 2008; 181(2): 1001 - 1011.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.